Investors
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 10, 2024
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...
-
Sep 3, 2024
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Lucid...
-
Aug 20, 2024
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...
-
Aug 13, 2024
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid...
-
Aug 12, 2024
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume...
-
Aug 8, 2024
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...
-
Aug 6, 2024
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lucid...
-
Aug 5, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...
-
Jul 29, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...
-
Jul 23, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM),...
-
Jul 11, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM),...
-
Jul 2, 2024
Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA...
-
Jun 12, 2024
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics...
-
May 13, 2024
Quarterly EsoGuard® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for...
-
May 9, 2024
EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection...
-
May 7, 2024
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in...
-
May 2, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 2, 2024
EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication...
-
Apr 29, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is...
-
Apr 8, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Mar 25, 2024
Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to...
-
Mar 21, 2024
Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% compared to upper gastrointestinal endoscopy Authors conclude that...
-
Mar 20, 2024
Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia NEW YORK, March 20, 2024...
-
Mar 12, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Feb 16, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Feb 15, 2024
Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology innovation NEW YORK, Feb. 15, 2024...
-
Feb 8, 2024
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("
-
Dec 12, 2023
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...
-
Dec 11, 2023
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock NEW YORK, Dec. 11, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq:...
-
Dec 4, 2023
PAVmed shareholders as of January 15, 2024 will participate in distribution of approximately 3.3 million shares of Lucid common stock 1-for-15 reverse stock split to be effective as of market open on
-
Nov 16, 2023
Industry veterans join executive team as VP, Market Access and VP, Employer Markets Shaun M. O'Neil promoted to Lucid's President and COO NEW YORK, Nov. 16, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.
-
Nov 14, 2023
Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conference call and...
-
Nov 13, 2023
Quarterly EsoGuard® test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be held tomorrow, November 14th at 8:30 AM EST NEW YORK,...
-
Nov 9, 2023
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs Lucid Diagnostics Investor Day,...
-
Nov 2, 2023
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...
-
Nov 1, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Oct 31, 2023
Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and firefighters, respectively Initial combined...
-
Oct 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Sep 21, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...
-
Sep 7, 2023
Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...
-
Sep 6, 2023
Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making Timely results support recently proposed federal legislation which seeks to fund...
-
Aug 24, 2023
EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
-
Aug 14, 2023
Quarterly EsoGuard® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to claims processing and payments
-
Jul 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jul 26, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jun 5, 2023
First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida NEW YORK, June 5, 2023 /PRNewswire/ --
-
May 15, 2023
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16th at 8:30 AM EST NEW YORK, May 15, 2023 /PRNewswire/...
-
May 11, 2023
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic...
May 5, 2023Conference Call and Webcast at 8:30AM Eastern TimePAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
May 5, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
- Apr 25, 2023Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
- Apr 19, 2023Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m. CDT.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Apr 18, 2023
Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdiction Noridian's foundational LCD, to become effective May 28, 2023, closely aligns with the LCD...
-
Apr 17, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
Mar 31, 2023Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testingLucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
- Mar 14, 2023Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
- Mar 13, 2023
In the news release, Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results, issued 13-Mar-2023 by Lucid Diagnostics over PR Newswire, we are advised by...
- Mar 3, 2023Conference Call and Webcast at 8:30AM Eastern Time
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
- Mar 3, 2023Conference Call and Webcast at 8:30AM Eastern Time
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
- Feb 15, 2023Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over two weekends, averaging nearly 100 tests per day
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jan 17, 2023Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital...
-
Jan 11, 2023Companies to host Conference Call at 4:30 PM EDT on Tuesday, January 17, 2023
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors,...
-
Dec 22, 2022License option and joint R&D agreement seek to apply Novosound’s groundbreaking flexible thin-film ultrasound technology to intravascular imaging
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
-
Dec 15, 2022Executes first commercial contract with leading New Jersey oncology practice
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital...
-
Dec 8, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned...
-
Dec 1, 2022EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Nov 15, 2022EsoGuard test volume shows steady sequential growth
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
Nov 14, 2022EsoGuard test volume increased 28% sequentially and 436% annually
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned...
-
Nov 11, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device,...
-
Nov 10, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
-
Nov 9, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
-
Nov 3, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call...
-
Nov 2, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Aug 30, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device,...
-
Aug 16, 2022Lucid’s EsoGuard test volume grows 60% and LucidDx Labs fully operational
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
Aug 15, 2022EsoGuard test volume increased 60% for quarter and over 300% annually
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of
-
Aug 11, 2022Patients in Orange County, Dallas-Fort Worth, Palm Beach County, and Columbus, Ohio now have access to a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Aug 4, 2022Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Aug 3, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call on...
-
Aug 2, 2022Agreements with three PPOs and a specialized laboratory network expand Lucid’s reach, providing in-network access and payment for its EsoGuard® DNA test to millions of additional covered lives
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
-
Aug 1, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Jul 19, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital...
-
Jul 18, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
May 13, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc....
-
May 12, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
May 11, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
May 9, 2022Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard® DNA test to over 8 million covered lives
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
- Apr 28, 2022
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a...
-
Apr 25, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Apr 4, 2022Updated American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard® on samples collected with EsoCheck®
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
-
Mar 30, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 28, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
-
Mar 24, 2022Cleveland VA enrolls first patient in DoD-funded study of EsoGuard’s impact in improving efficiency and cost-effectiveness of early detection of esophageal precancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 23, 2022Patients in Seattle, Portland, and Boise metropolitan areas now have access to a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 7, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Mar 4, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 3, 2022New wholly owned Lucid subsidiary now performing EsoGuard® Esophageal DNA Test in its own new state-of-the-art CLIA-certified, CAP-accredited clinical laboratory
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Feb 10, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Jan 12, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc....
-
Jan 6, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....